Skip to main content
Clinical Trials/NCT04897373
NCT04897373
Completed
N/A

The Effects of an Active Older Adult Program at the Dan Abraham Healthy Living Center on Health and Well-being

Mayo Clinic1 site in 1 country33 target enrollmentAugust 7, 2018
ConditionsOlder Adult

Overview

Phase
N/A
Intervention
Not specified
Conditions
Older Adult
Sponsor
Mayo Clinic
Enrollment
33
Locations
1
Primary Endpoint
Change in repeated chair rise time
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this study is to determine whether a structured 12-week program designed for older adults will improve physical function and, in parallel, circulating biomarkers of aging

Registry
clinicaltrials.gov
Start Date
August 7, 2018
End Date
April 2, 2020
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Nathan K. LeBrasseur

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Men and women age 55 years or older.
  • Membership at the DAHLC.
  • New to AOA (Active Older Adult) Program and commitment to full participation in the twelve-week program.
  • Must be able to get down and off the floor with little assistance.

Exclusion Criteria

  • Inability to provide informed consent.
  • Previous participation in the AOA Program at the DAHLC.

Outcomes

Primary Outcomes

Change in repeated chair rise time

Time Frame: Baseline to end of study, approximately 14 weeks

Chair stand test where participants will perform a chair rise movement for five repetitions. The series of 5 repetitions will be timed and measured in seconds.

Change in plasma protein levels reflective of biological age

Time Frame: Baseline, week 12

Blood samples will be obtained at baseline and at 12 weeks. The concentration of target proteins (pg/mL) in the plasma will be measured and compared between baseline and week 12.

Change in expression of senescence-related genes in blood cells

Time Frame: Baseline, week 12

Blood samples will be obtained at baseline and at 12 weeks. The expression of senescence-related genes (arbitrary units) will be measured in immune cells isolated from whole blood and compared between baseline and week 12.

Secondary Outcomes

  • Change in Self-reported Physical Function(Baseline, week 12)
  • Change in Performance-based Physical Function(Baseline, week 12)
  • Change in Mental Function(Baseline, week 12)
  • Change in self-assessment of well-being(Baseline, week 12)

Study Sites (1)

Loading locations...

Similar Trials